Three catalysts remaining this year, each with a different weight:
**1. FDA IND Clearance — Expected Q2 2026** Allows Phase 2 to include US clinical sites. This is largely administrative at this stage — IND clearance for a drug that's already completed Phase 1 and Phase 1b elsewhere is not a high-risk event, but it's a gating item for the US Phase 2 timeline. If it gets delayed it pushes everything else back.
**2. Phase 2 Initiation — Expected Q3 2026** This is the most visible near-term milestone. A Phase 2 start confirms the program is advancing and tends to generate attention for clinical-stage names. It doesn't tell you anything about efficacy yet but it moves the story forward concretely.
**3. Full Phase 1b Results — Expected Q4 2026** This is the most analytically meaningful catalyst of the three. The full dataset from the nine-month extension will include longer-term biomarker and clinical data with the complete 16-participant population. This is when you get the most complete picture of GT-02287's disease-modifying signal before Phase 2 readouts become available.
There's also a presentation at the 3rd International GBA1 Meeting in Phoenix later in May where additional Phase 1b data is expected to be shared. Smaller near-term event but worth watching for any incremental data.
**The risk sitting alongside all of this:** $16.5M in cash as of March 31, burning roughly $4-5M per quarter before Phase 2 costs kick in. A capital raise is likely somewhere in this timeline. Dilution is a real consideration alongside every catalyst above.
This is not financial advice!!! It's important to do your own DD before making any investment decisions. - [1](https://finance.yahoo.com/quote/GANX/), [2](https://gaintherapeutics.com/), [3](https://stockresearchtoday.com/ganx/)